Pharsight

Pfizer patents expiration

1. Arthrotec patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5601843 PFIZER Pharmaceutical tablet composition
Feb, 2014

(10 years ago)

Drugs and Companies using DICLOFENAC SODIUM; MISOPROSTOL ingredient

Market Authorisation Date: 24 December, 1997

Treatment: NA

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of ARTHROTEC before it's drug patent expiration?
More Information on Dosage

ARTHROTEC family patents

Family Patents

2. Caverject patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5741523 PFIZER Stabilized prostaglandin E1
Apr, 2015

(9 years ago)

Drugs and Companies using ALPROSTADIL ingredient

Market Authorisation Date: 27 June, 1996

Treatment: NA

Dosage: INJECTABLE;INJECTION

More Information on Dosage

CAVERJECT family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Caverject Impulse patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5501673 PFIZER Injection cartridge
Apr, 2013

(11 years ago)

US5716338 PFIZER Dual-chamber type injection cartridge with bypass connection
Feb, 2015

(9 years ago)

Drugs and Companies using ALPROSTADIL ingredient

Market Authorisation Date: 11 June, 2002

Treatment: NA

Dosage: INJECTABLE;INJECTION

More Information on Dosage

CAVERJECT IMPULSE family patents

Family Patents

4. Cibinqo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9545405 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(9 years from now)

US9035074 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549929 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 14, 2027
New Patient Population(NPP) Feb 09, 2026

Drugs and Companies using ABROCITINIB ingredient

NCE-1 date: 14 January, 2026

Market Authorisation Date: 14 January, 2022

Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable

Dosage: TABLET;ORAL

More Information on Dosage

CIBINQO family patents

Family Patents

5. Cleocin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6495157 PFIZER Intravaginal clindamycin ovule composition
Jul, 2020

(3 years ago)

Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 13 August, 1999

Treatment: NA

Dosage: SUPPOSITORY;VAGINAL

More Information on Dosage

CLEOCIN family patents

Family Patents

6. Colestid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5490987 PFIZER Tableting of colestipol hydrochloride
Feb, 2013

(11 years ago)

Drugs and Companies using COLESTIPOL HYDROCHLORIDE ingredient

Market Authorisation Date: 19 July, 1994

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

COLESTID family patents

Family Patents

7. Covera-hs patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6096339 PFIZER Dosage form, process of making and using same
Apr, 2017

(7 years ago)

Drugs and Companies using VERAPAMIL HYDROCHLORIDE ingredient

Market Authorisation Date: 26 February, 1996

Treatment: Method for the treatment of cardiovascular disease through the administration of a calcium blocking vasodilator in our extended, controlled release formulation

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of COVERA-HS before it's drug patent expiration?
More Information on Dosage

COVERA-HS family patents

Family Patents

8. Daurismo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8148401 PFIZER Benzimidazole derivatives
Jan, 2031

(6 years from now)

US10414748 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Apr, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431597 PFIZER Benzimidazole derivatives
Jun, 2028

(4 years from now)

US11168066 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Apr, 2036

(11 years from now)

US11891372 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Apr, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-224) Nov 21, 2025
New Chemical Entity Exclusivity(NCE) Nov 21, 2023

Drugs and Companies using GLASDEGIB MALEATE ingredient

NCE-1 date: 21 November, 2022

Market Authorisation Date: 21 November, 2018

Treatment: Use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >= 75 years old or who have comorbidities that preclude use of...

Dosage: TABLET;ORAL

More Information on Dosage

DAURISMO family patents

Family Patents

9. Depo-subq Provera 104 patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6495534 PFIZER Stabilized aqueous suspensions for parenteral use
May, 2020

(4 years ago)

Drugs and Companies using MEDROXYPROGESTERONE ACETATE ingredient

Market Authorisation Date: 17 December, 2004

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

DEPO-SUBQ PROVERA 104 family patents

Family Patents

10. Elelyso patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8741620 PFIZER Human lysosomal proteins from plant cell culture
Feb, 2024

(3 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8227230 PFIZER Human lysosomal proteins from plant cell culture
Feb, 2024

(3 months ago)

US8790641 PFIZER Production of high mannose proteins in plant culture and therapeutic uses thereof
Oct, 2025

(1 year, 4 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Aug 27, 2017
New Chemical Entity Exclusivity(NCE) May 01, 2017

Drugs and Companies using TALIGLUCERASE ALFA ingredient

NCE-1 date: 01 May, 2016

Market Authorisation Date: 01 May, 2012

Treatment: A method of catalyzing the hydrolysis of glucocerebroside to glucose and ceramide.

Dosage: POWDER;IV (INFUSION)

More Information on Dosage

ELELYSO family patents

Family Patents

11. Exubera patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6592904 PFIZER Dispersible macromolecule compositions and methods for their preparation and use
Mar, 2014

(10 years ago)

US6423344 PFIZER Dispersible macromolecule compositions and methods for their preparation and use
Mar, 2014

(10 years ago)

US5997848 PFIZER Methods and compositions for pulmonary delivery of insulin
Mar, 2014

(10 years ago)

US6051256 PFIZER Dispersible macromolecule compositions and methods for their preparation and use
Mar, 2014

(10 years ago)

US6737045 PFIZER Methods and compositions for the pulmonary delivery insulin
Mar, 2014

(10 years ago)

US6543448 PFIZER Apparatus and methods for dispersing dry powder medicaments
Sep, 2014

(9 years ago)

US5740794 PFIZER Apparatus and methods for dispersing dry powder medicaments
Apr, 2015

(9 years ago)

US6685967 PFIZER Methods and compositions for pulmonary delivery of insulin
Sep, 2018

(5 years ago)

US6546929 PFIZER Dry powder dispersing apparatus and methods for their use
May, 2019

(5 years ago)

US6257233 PFIZER Dry powder dispersing apparatus and methods for their use
May, 2019

(5 years ago)

US6582728 PFIZER Spray drying of macromolecules to produce inhaleable dry powders
Jun, 2020

(3 years ago)

Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient

Market Authorisation Date: 27 January, 2006

Treatment: Method of administering insulin via inhalation

Dosage: POWDER;INHALATION

More Information on Dosage

EXUBERA family patents

Family Patents

12. Flagyl Er patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6103262 PFIZER Modified-release metronidazole compositions and methods for making and using same
Aug, 2017

(6 years ago)

Drugs and Companies using METRONIDAZOLE ingredient

Market Authorisation Date: 26 November, 1997

Treatment: Method of treating bacterial vaginosis

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

FLAGYL ER family patents

Family Patents

13. Glucotrol Xl patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5591454 PFIZER Method for lowering blood glucose
Jan, 2014

(10 years ago)

USRE44459 PFIZER Method for lowering blood glucose
Mar, 2019

(5 years ago)

Drugs and Companies using GLIPIZIDE ingredient

Market Authorisation Date: 10 August, 1999

Treatment: Method of use for controlling hyperglycemia by administration of this sustained release dosage form of glipizide; Method of treating hyperglycemia to improve glycemic control in a patient by oral admi...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of GLUCOTROL XL before it's drug patent expiration?
More Information on Dosage

GLUCOTROL XL family patents

Family Patents

14. Ibrance patents expiration

IBRANCE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6936612 PFIZER 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
Jan, 2023

(1 year, 4 months ago)

US7208489 PFIZER 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
Jan, 2023

(1 year, 4 months ago)

USRE47739 PFIZER 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones
Mar, 2027

(2 years from now)

US10723730 PFIZER Solid forms of a selective CDK4/6 inhibitor
Feb, 2034

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7456168 PFIZER 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones
Jan, 2023

(1 year, 4 months ago)

US11065250 PFIZER Solid dosage forms of palbociclib
Aug, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 03, 2020

Drugs and Companies using PALBOCICLIB ingredient

NCE-1 date: 03 February, 2019

Market Authorisation Date: 01 November, 2019

Treatment: Palbociclib for hr-pos. her2-neg. advanced or metastatic breast cancer in combo with an aromatase inhibitor in pts as initial endocrine-based therapy or with fulvestrant with disease progression after...

Dosage: TABLET;ORAL

How can I launch a generic of IBRANCE before it's drug patent expiration?
More Information on Dosage

IBRANCE family patents

Family Patents

15. Litfulo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9617258 PFIZER Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
Dec, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 23, 2028

Drugs and Companies using RITLECITINIB TOSYLATE ingredient

NCE-1 date: 24 June, 2027

Market Authorisation Date: 23 June, 2023

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

LITFULO family patents

Family Patents

16. Lorbrena patents expiration

Can you believe LORBRENA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8680111 PFIZER Macrocyclic derivatives for the treatment of diseases
Mar, 2033

(8 years from now)

US10420749 PFIZER Crystalline form of lorlatinib free base
Jul, 2036

(12 years from now)

US11299500 PFIZER Crystalline form of lorlatinib free base hydrate
Oct, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020376 PFIZER Crystalline form of lorlatinib free base
Jul, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-218) Nov 02, 2025
Orphan Drug Exclusivity(ODE-219) Nov 02, 2025
Orphan Drug Exclusivity(ODE-217) Nov 02, 2025
Orphan Drug Exclusivity(ODE-349) Mar 03, 2028
New Indication(I-847) Mar 03, 2024
New Chemical Entity Exclusivity(NCE) Nov 02, 2023

Drugs and Companies using LORLATINIB ingredient

NCE-1 date: 02 November, 2022

Market Authorisation Date: 02 November, 2018

Treatment: Treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-positive as detected by an fda-approved test

Dosage: TABLET;ORAL

More Information on Dosage

LORBRENA family patents

Family Patents

17. Nurtec Odt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8314117 PFIZER CGRP receptor antagonists
Mar, 2030

(5 years from now)

US8759372 PFIZER N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt
Feb, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11083724 PFIZER Rimegepant for CGRP related disorders
Mar, 2039

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 27, 2025
New Indication(I-865) May 27, 2024

Drugs and Companies using RIMEGEPANT SULFATE ingredient

NCE-1 date: 28 February, 2024

Market Authorisation Date: 27 February, 2020

Treatment: Preventive treatment of episodic migraine in adults

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

NURTEC ODT family patents

Family Patents

18. Paxlovid (copackaged) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11351149 PFIZER Nitrile-containing antiviral compounds
Aug, 2041

(17 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11541034 PFIZER Nitrile-containing antiviral compounds
Oct, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 25, 2028

Drugs and Companies using NIRMATRELVIR; RITONAVIR ingredient

NCE-1 date: 26 May, 2027

Market Authorisation Date: 25 May, 2023

Treatment: Treatment of mild-to-moderate coronavirus disease 2019 (covid-19) in adults who are at high risk for progression to severe covid-19, including hospitalization or death

Dosage: TABLET;ORAL

More Information on Dosage

PAXLOVID (COPACKAGED) family patents

Family Patents

19. Talzenna patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8420650 PFIZER Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Jul, 2029

(5 years from now)

US8012976 PFIZER Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Oct, 2029

(5 years from now)

US10189837 PFIZER Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Oct, 2031

(7 years from now)

US8735392 PFIZER Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Oct, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9820985 PFIZER Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Jul, 2029

(5 years from now)

US10780088 PFIZER Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Jul, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-920) Jun 20, 2026

Drugs and Companies using TALAZOPARIB TOSYLATE ingredient

Market Authorisation Date: 07 March, 2024

Treatment: Treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (brca)-mutated (gbrcam) human epidermal growth factor receptor 2 (her2)-negative locall...

Dosage: CAPSULE;ORAL

More Information on Dosage

TALZENNA family patents

Family Patents

20. Tikosyn patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US4959366 PFIZER Anti-arrhythmic agents
Sep, 2012

(11 years ago)

US6124363 PFIZER Dofetilide polymorphs
Oct, 2018

(5 years ago)

Drugs and Companies using DOFETILIDE ingredient

Market Authorisation Date: 01 October, 1999

Treatment: Treatment of cardiac arrhythmia

Dosage: CAPSULE;ORAL

How can I launch a generic of TIKOSYN before it's drug patent expiration?
More Information on Dosage

TIKOSYN family patents

Family Patents

21. Toviaz patents expiration

TOVIAZ IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7384980 PFIZER Derivatives of 3,3-diphenylpropylamines
May, 2019

(5 years ago)

US7855230 PFIZER Derivatives of 3,3-diphenylpropylamines
May, 2019

(5 years ago)

US8338478 PFIZER Derivatives of 3,3-diphenylpropylamines
May, 2019

(5 years ago)

US7985772 PFIZER Derivatives of 3,3-diphenylpropylamines
May, 2019

(5 years ago)

US6858650 PFIZER Stable salts of novel derivatives of 3,3-diphenylpropylamines
Jul, 2022

(1 year, 11 months ago)

US6858650

(Pediatric)

PFIZER Stable salts of novel derivatives of 3,3-diphenylpropylamines
Jan, 2023

(1 year, 5 months ago)

US7807715 PFIZER Pharmaceutical compositions comprising fesoterodine
Jun, 2027

(2 years from now)

US8088398 PFIZER Pharmaceutical compositions comprising fesoterodine
Jun, 2027

(2 years from now)

US8501723 PFIZER Pharmaceutical compositions comprising fesoterodine
Jun, 2027

(2 years from now)

US8088398

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine
Dec, 2027

(3 years from now)

US7807715

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine
Dec, 2027

(3 years from now)

US8501723

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine
Dec, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-861) Jun 17, 2024
Pediatric Exclusivity(PED) Dec 17, 2024
New Chemical Entity Exclusivity(NCE) Oct 31, 2013

Drugs and Companies using FESOTERODINE FUMARATE ingredient

NCE-1 date: 18 December, 2023

Market Authorisation Date: 31 October, 2008

Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of TOVIAZ before it's drug patent expiration?
More Information on Dosage

TOVIAZ family patents

Family Patents

22. Trovan patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5763454 PFIZER Crystal form of anhydrous 7-( 1α,5α,6α!-6-amino-3-azabicyclo 3.1.0!hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanessulfonic acid salt
Jun, 2015

(9 years ago)

US6187341 PFIZER Trovafloxacin mesylate tablet
Jan, 2019

(5 years ago)

Drugs and Companies using TROVAFLOXACIN MESYLATE ingredient

Market Authorisation Date: 18 December, 1997

Treatment: Method of treating bacterial infections

Dosage: TABLET;ORAL

More Information on Dosage

TROVAN family patents

Family Patents

23. Trovan Preservative Free patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5763454 PFIZER Crystal form of anhydrous 7-( 1α,5α,6α!-6-amino-3-azabicyclo 3.1.0!hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanessulfonic acid salt
Jun, 2015

(9 years ago)

US6080756 PFIZER Polymorphs of the prodrug 6-N-(L-ALA-L-ALA)-trovafloxacin
Jul, 2016

(7 years ago)

US6194429 PFIZER Alatrofloxacin parenteral compositions
Jul, 2018

(5 years ago)

Drugs and Companies using ALATROFLOXACIN MESYLATE ingredient

Market Authorisation Date: 18 December, 1997

Treatment: Method of treating bacterial infections

Dosage: INJECTABLE;INJECTION

More Information on Dosage

TROVAN PRESERVATIVE FREE family patents

Family Patents

24. Troxyca Er patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685443 PFIZER Sequestering subunit and related compositions and methods
Jul, 2025

(1 year, 19 days from now)

US7815934 PFIZER Sequestering subunit and related compositions and methods
Dec, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Aug 19, 2019

Drugs and Companies using NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 August, 2016

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

TROXYCA ER family patents

Family Patents

25. Velsipity patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8580841 PFIZER Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
Mar, 2030

(5 years from now)

US10301262 PFIZER Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders
Jun, 2036

(12 years from now)

US11091435 PFIZER Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in S1P1 receptor-associated disorders
Jun, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9126932 PFIZER Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
Jul, 2029

(5 years from now)

US11007175 PFIZER Methods of treating conditions related to the S1P1 receptor
Jan, 2036

(11 years from now)

US11884626 PFIZER Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders
Jun, 2036

(12 years from now)

US10676435 PFIZER Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disorders
Jun, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 12, 2028

Drugs and Companies using ETRASIMOD ARGININE ingredient

NCE-1 date: 13 October, 2027

Market Authorisation Date: 12 October, 2023

Treatment: A method for treating ulcerative colitis by administering a therapeutically effective amount of estrasimod arginine; A method for treating ulcerative colitis by administering estrasimod arginine in an...

Dosage: TABLET;ORAL

More Information on Dosage

VELSIPITY family patents

Family Patents

26. Vizimpro patents expiration

VIZIMPRO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7772243 PFIZER 4-phenylamino-quinazolin-6-yl-amides
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623883 PFIZER 4-phenylamino-quinazolin-6-yl-amides
May, 2025

(10 months from now)

US10603314 PFIZER Method for treating gefitinib resistant cancer
Feb, 2026

(1 year, 7 months from now)

US10596162 PFIZER Method for treating gefitinib resistant cancer
Feb, 2026

(1 year, 7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-206) Sep 27, 2025
Orphan Drug Exclusivity(ODE-213) Sep 27, 2025
New Chemical Entity Exclusivity(NCE) Sep 27, 2023

Drugs and Companies using DACOMITINIB ingredient

NCE-1 date: 27 September, 2022

Market Authorisation Date: 27 September, 2018

Treatment: First-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test; Administering daily a u...

Dosage: TABLET;ORAL

More Information on Dosage

VIZIMPRO family patents

Family Patents

27. Xeljanz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE41783 PFIZER Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(1 year, 5 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 25, 2023

Drugs and Companies using TOFACITINIB CITRATE ingredient

Market Authorisation Date: 25 September, 2020

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of XELJANZ before it's drug patent expiration?
More Information on Dosage

XELJANZ family patents

Family Patents

28. Xeljanz Xr patents expiration

XELJANZ XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7265221 PFIZER Pyrrolo[2,3-d]pyrimidine compounds
Dec, 2020

(3 years ago)

US7301023 PFIZER Chiral salt resolution
Dec, 2020

(3 years ago)

US6965027 PFIZER Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
Mar, 2023

(1 year, 2 months ago)

US6956027 PFIZER N-terminally chemically modified protein compositions and methods
Mar, 2023

(1 year, 2 months ago)

USRE41783 PFIZER Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(1 year, 5 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6956041 PFIZER Pyrrolo[2,3-d]pyrimidine compounds
Dec, 2020

(3 years ago)

US7842699 PFIZER Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2020

(3 years ago)

US7091208 PFIZER Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2020

(3 years ago)

US11253523 PFIZER Tofacitinib oral sustained release dosage forms
Mar, 2034

(9 years from now)

US9937181 PFIZER Tofacitinib oral sustained release dosage forms
Mar, 2034

(9 years from now)

US10639309 PFIZER Tofacitinib oral sustained release dosage forms
Mar, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-879) Dec 14, 2024
New Indication(I-761) Dec 14, 2020
New Chemical Entity Exclusivity(NCE) Nov 06, 2017

Drugs and Companies using TOFACITINIB CITRATE ingredient

NCE-1 date: 06 November, 2016

Market Authorisation Date: 23 February, 2016

Treatment: Treatment of adult patients with moderately to severely active ulcerative colitis (uc); Treatment of rheumatoid arthritis; A method of treating ulcerative colitis, by administering the formulation of ...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of XELJANZ XR before it's drug patent expiration?
More Information on Dosage

XELJANZ XR family patents

Family Patents

29. Zavzpret patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7220862 PFIZER Calcitonin gene related peptide receptor antagonists
Jan, 2024

(4 months ago)

US8481546 PFIZER CGRP receptor antagonist
Oct, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7314883 PFIZER Anti-migraine treatments
Dec, 2023

(6 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 09, 2028

Drugs and Companies using ZAVEGEPANT HYDROCHLORIDE ingredient

NCE-1 date: 10 March, 2027

Market Authorisation Date: 09 March, 2023

Treatment: Administration of zavegepant for acute treatment of migraine with or without aura

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

ZAVZPRET family patents

Family Patents

30. Zithromax patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6268489 PFIZER Azithromycin dihydrate
Jul, 2018

(5 years ago)

Drugs and Companies using AZITHROMYCIN ingredient

Market Authorisation Date: 19 October, 1995

Treatment: NA

Dosage: FOR SUSPENSION;ORAL; TABLET;ORAL; INJECTABLE;INJECTION

More Information on Dosage

ZITHROMAX family patents

Family Patents

31. Zyvox patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6559305 PFIZER Linezolid—crystal form II
Jan, 2021

(3 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5688792 PFIZER Substituted oxazine and thiazine oxazolidinone antimicrobials
Nov, 2014

(9 years ago)

US5688792

(Pediatric)

PFIZER Substituted oxazine and thiazine oxazolidinone antimicrobials
May, 2015

(9 years ago)

US6559305 PFIZER Linezolid—crystal form II
Jan, 2021

(3 years ago)

US6514529 PFIZER Oxazolidinone tablet formulation
Mar, 2021

(3 years ago)

US6559305

(Pediatric)

PFIZER Linezolid—crystal form II
Jul, 2021

(2 years ago)

US6514529

(Pediatric)

PFIZER Oxazolidinone tablet formulation
Sep, 2021

(2 years ago)

Drugs and Companies using LINEZOLID ingredient

Market Authorisation Date: 18 April, 2000

Treatment: Treatment of microbial infections

Dosage: TABLET;ORAL; FOR SUSPENSION;ORAL; SOLUTION;INTRAVENOUS

How can I launch a generic of ZYVOX before it's drug patent expiration?
More Information on Dosage

ZYVOX family patents

Family Patents